Cargando…

Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum

The concept of the cardiovascular continuum, introduced during the early 1990s, created a holistic view of the chain of events connecting cardiovascular-related risk factors with the progressive development of pathological-related tissue remodelling and ultimately, heart failure and death. Understan...

Descripción completa

Detalles Bibliográficos
Autores principales: Vassiliadis, Efstathios, Barascuk, Natasha, Didangelos, Athanasios, Karsdal, Morten A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347891/
https://www.ncbi.nlm.nih.gov/pubmed/22577298
http://dx.doi.org/10.4137/BMI.S9536
_version_ 1782232341315321856
author Vassiliadis, Efstathios
Barascuk, Natasha
Didangelos, Athanasios
Karsdal, Morten A
author_facet Vassiliadis, Efstathios
Barascuk, Natasha
Didangelos, Athanasios
Karsdal, Morten A
author_sort Vassiliadis, Efstathios
collection PubMed
description The concept of the cardiovascular continuum, introduced during the early 1990s, created a holistic view of the chain of events connecting cardiovascular-related risk factors with the progressive development of pathological-related tissue remodelling and ultimately, heart failure and death. Understanding of the tissue-specific changes, and new technologies developed over the last 25–30 years, enabled tissue remodelling events to be monitored in vivo and cardiovascular disease to be diagnosed more reliably than before. The tangible product of this evolution was the introduction of a number of biochemical markers such as troponin I and T, which are now commonly used in clinics to measure myocardial damage. However, biomarkers that can detect specific earlier stages of the cardiovascular continuum have yet to be generated and utilised. The majority of the existing markers are useful only in the end stages of the disease where few successful intervention options exist. Since a large number of patients experience a transient underlying developing pathology long before the signs or symptoms of cardiovascular disease become apparent, the requirement for new markers that can describe the early tissue-specific, matrix remodelling process which ultimately leads to disease is evident. This review highlights the importance of relating cardiac biochemical markers with specific time points along the cardiovascular continuum, especially during the early transient phase of pathology progression where none of the existing markers aid diagnosis.
format Online
Article
Text
id pubmed-3347891
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-33478912012-05-10 Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum Vassiliadis, Efstathios Barascuk, Natasha Didangelos, Athanasios Karsdal, Morten A Biomark Insights Perspective The concept of the cardiovascular continuum, introduced during the early 1990s, created a holistic view of the chain of events connecting cardiovascular-related risk factors with the progressive development of pathological-related tissue remodelling and ultimately, heart failure and death. Understanding of the tissue-specific changes, and new technologies developed over the last 25–30 years, enabled tissue remodelling events to be monitored in vivo and cardiovascular disease to be diagnosed more reliably than before. The tangible product of this evolution was the introduction of a number of biochemical markers such as troponin I and T, which are now commonly used in clinics to measure myocardial damage. However, biomarkers that can detect specific earlier stages of the cardiovascular continuum have yet to be generated and utilised. The majority of the existing markers are useful only in the end stages of the disease where few successful intervention options exist. Since a large number of patients experience a transient underlying developing pathology long before the signs or symptoms of cardiovascular disease become apparent, the requirement for new markers that can describe the early tissue-specific, matrix remodelling process which ultimately leads to disease is evident. This review highlights the importance of relating cardiac biochemical markers with specific time points along the cardiovascular continuum, especially during the early transient phase of pathology progression where none of the existing markers aid diagnosis. Libertas Academica 2012-05-02 /pmc/articles/PMC3347891/ /pubmed/22577298 http://dx.doi.org/10.4137/BMI.S9536 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Perspective
Vassiliadis, Efstathios
Barascuk, Natasha
Didangelos, Athanasios
Karsdal, Morten A
Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum
title Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum
title_full Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum
title_fullStr Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum
title_full_unstemmed Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum
title_short Novel Cardiac-Specific Biomarkers and the Cardiovascular Continuum
title_sort novel cardiac-specific biomarkers and the cardiovascular continuum
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347891/
https://www.ncbi.nlm.nih.gov/pubmed/22577298
http://dx.doi.org/10.4137/BMI.S9536
work_keys_str_mv AT vassiliadisefstathios novelcardiacspecificbiomarkersandthecardiovascularcontinuum
AT barascuknatasha novelcardiacspecificbiomarkersandthecardiovascularcontinuum
AT didangelosathanasios novelcardiacspecificbiomarkersandthecardiovascularcontinuum
AT karsdalmortena novelcardiacspecificbiomarkersandthecardiovascularcontinuum